About Index Trending news
Lists
Pricing
Sequenta

Sequenta

Sequenta

is dedicated to improving patient care in diseases mediated by immune cells. Our ClonoSIGHT™ test for MRD in lymphoid cancers launched in 2013.

Elsewhere

Alexa global traffic share

Twitter followers

02 Jul 2013
$20,000,000
Venture capital (Series C)
01 Jan 2012
$8,460,000
Undisclosed funding
08 Dec 2010
$13,000,000
Venture capital (Series B)